Bio Common Stock vs Total Liab Analysis

BGT Stock

0.04 0 2.33%

Bio Gene financial indicator trend analysis is way more than just evaluating Bio Gene Technology prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bio Gene Technology is a good investment. Please check the relationship between Bio Gene Common Stock and its Total Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Gene Technology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Common Stock vs Total Liab

Common Stock vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bio Gene Technology Common Stock account and Total Liab. At this time, the significance of the direction appears to have strong relationship.

The correlation between Bio Gene's Common Stock and Total Liab is 0.76. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Total Liab in the same time period over historical financial statements of Bio Gene Technology, assuming nothing else is changed. The correlation between historical values of Bio Gene's Common Stock and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Bio Gene Technology are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Common Stock i.e., Bio Gene's Common Stock and Total Liab go up and down completely randomly.

Correlation Coefficient

0.76

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Common Stock

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Bio Gene's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bio Gene Technology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Gene Technology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Selling General Administrative is likely to gain to about 1.5 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 2.2 M in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	43.5K	45.3K	38.4K	37.4K
Interest Income	52.9K	86.0K	87.0K	60.7K

Reconciled Depreciation Interest Income

Bio Gene fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment	Net Receivables	Other Liab	Accounts Payable	Non Current Liabilities Total	Inventory	Short Long Term Debt Total
Total Assets		0.83	0.75	1.0	0.73	0.81	-0.98	-0.43	1.0	0.65	-0.33	1.0	0.54	0.34	0.69	0.75	1.0	0.63	0.71	0.81	0.65	-0.74	0.94	-0.75	0.69	0.13
Other Current Liab	0.83		0.97	0.8	0.81	0.55	-0.79	-0.71	0.81	0.36	-0.1	0.81	0.73	0.56	0.86	0.89	0.84	0.34	0.87	0.54	0.77	-0.88	0.83	-0.88	0.85	0.13
Total Current Liabilities	0.75	0.97		0.71	0.86	0.55	-0.71	-0.73	0.72	0.3	-0.08	0.72	0.7	0.48	0.9	0.92	0.76	0.28	0.85	0.55	0.82	-0.85	0.76	-0.85	0.91	0.14
Total Stockholder Equity	1.0	0.8	0.71		0.7	0.8	-0.99	-0.4	1.0	0.64	-0.33	1.0	0.51	0.3	0.65	0.71	1.0	0.62	0.69	0.8	0.61	-0.72	0.94	-0.72	0.65	0.13
Net Tangible Assets	0.73	0.81	0.86	0.7		0.62	-0.69	-0.8	0.69	0.31	0.05	0.69	0.8	0.37	0.9	0.78	0.73	0.27	0.94	0.6	0.9	-0.91	0.69	-0.91	0.92	0.43
Property Plant And Equipment Net	0.81	0.55	0.55	0.8	0.62		-0.77	-0.3	0.79	0.88	-0.44	0.79	0.46	0.3	0.6	0.67	0.8	0.86	0.51	1.0	0.68	-0.54	0.69	-0.55	0.61	0.21
Net Debt	-0.98	-0.79	-0.71	-0.99	-0.69	-0.77		0.32	-0.99	-0.65	0.43	-0.99	-0.47	-0.28	-0.63	-0.7	-0.98	-0.63	-0.66	-0.77	-0.57	0.66	-0.97	0.67	-0.62	-0.01
Retained Earnings	-0.43	-0.71	-0.73	-0.4	-0.8	-0.3	0.32		-0.39	0.0	-0.48	-0.39	-0.88	-0.57	-0.84	-0.63	-0.44	0.02	-0.89	-0.28	-0.83	0.91	-0.33	0.91	-0.84	-0.66
Cash	1.0	0.81	0.72	1.0	0.69	0.79	-0.99	-0.39		0.63	-0.34	1.0	0.5	0.3	0.64	0.71	1.0	0.61	0.68	0.79	0.59	-0.71	0.95	-0.72	0.64	0.1
Non Current Assets Total	0.65	0.36	0.3	0.64	0.31	0.88	-0.65	0.0	0.63		-0.7	0.63	0.31	0.37	0.31	0.47	0.63	1.0	0.25	0.88	0.43	-0.26	0.59	-0.26	0.28	-0.11
Non Currrent Assets Other	-0.33	-0.1	-0.08	-0.33	0.05	-0.44	0.43	-0.48	-0.34	-0.7		-0.34	0.18	0.02	0.04	-0.21	-0.32	-0.71	0.13	-0.46	0.01	-0.21	-0.47	-0.22	0.08	0.72
Cash And Short Term Investments	1.0	0.81	0.72	1.0	0.69	0.79	-0.99	-0.39	1.0	0.63	-0.34		0.5	0.3	0.64	0.71	1.0	0.61	0.68	0.79	0.59	-0.71	0.95	-0.72	0.64	0.1
Common Stock Shares Outstanding	0.54	0.73	0.7	0.51	0.8	0.46	-0.47	-0.88	0.5	0.31	0.18	0.5		0.79	0.85	0.71	0.54	0.3	0.91	0.43	0.85	-0.88	0.48	-0.88	0.76	0.51
Other Current Assets	0.34	0.56	0.48	0.3	0.37	0.3	-0.28	-0.57	0.3	0.37	0.02	0.3	0.79		0.6	0.57	0.33	0.37	0.57	0.28	0.56	-0.53	0.29	-0.53	0.42	0.25
Other Stockholder Equity	0.69	0.86	0.9	0.65	0.9	0.6	-0.63	-0.84	0.64	0.31	0.04	0.64	0.85	0.6		0.9	0.69	0.28	0.93	0.58	0.93	-0.88	0.64	-0.89	0.94	0.42
Total Liab	0.75	0.89	0.92	0.71	0.78	0.67	-0.7	-0.63	0.71	0.47	-0.21	0.71	0.71	0.57	0.9		0.75	0.45	0.76	0.67	0.81	-0.76	0.73	-0.76	0.85	0.1
Total Current Assets	1.0	0.84	0.76	1.0	0.73	0.8	-0.98	-0.44	1.0	0.63	-0.32	1.0	0.54	0.33	0.69	0.75		0.61	0.72	0.8	0.65	-0.75	0.95	-0.76	0.7	0.13
Intangible Assets	0.63	0.34	0.28	0.62	0.27	0.86	-0.63	0.02	0.61	1.0	-0.71	0.61	0.3	0.37	0.28	0.45	0.61		0.23	0.86	0.4	-0.23	0.57	-0.24	0.25	-0.13
Common Stock	0.71	0.87	0.85	0.69	0.94	0.51	-0.66	-0.89	0.68	0.25	0.13	0.68	0.91	0.57	0.93	0.76	0.72	0.23		0.49	0.9	-0.96	0.67	-0.96	0.9	0.47
Property Plant Equipment	0.81	0.54	0.55	0.8	0.6	1.0	-0.77	-0.28	0.79	0.88	-0.46	0.79	0.43	0.28	0.58	0.67	0.8	0.86	0.49		0.66	-0.52	0.69	-0.53	0.6	0.18
Net Receivables	0.65	0.77	0.82	0.61	0.9	0.68	-0.57	-0.83	0.59	0.43	0.01	0.59	0.85	0.56	0.93	0.81	0.65	0.4	0.9	0.66		-0.86	0.54	-0.86	0.95	0.46
Other Liab	-0.74	-0.88	-0.85	-0.72	-0.91	-0.54	0.66	0.91	-0.71	-0.26	-0.21	-0.71	-0.88	-0.53	-0.88	-0.76	-0.75	-0.23	-0.96	-0.52	-0.86		-0.66	1.0	-0.89	-0.51
Accounts Payable	0.94	0.83	0.76	0.94	0.69	0.69	-0.97	-0.33	0.95	0.59	-0.47	0.95	0.48	0.29	0.64	0.73	0.95	0.57	0.67	0.69	0.54	-0.66		-0.67	0.6	-0.1
Non Current Liabilities Total	-0.75	-0.88	-0.85	-0.72	-0.91	-0.55	0.67	0.91	-0.72	-0.26	-0.22	-0.72	-0.88	-0.53	-0.89	-0.76	-0.76	-0.24	-0.96	-0.53	-0.86	1.0	-0.67		-0.89	-0.52
Inventory	0.69	0.85	0.91	0.65	0.92	0.61	-0.62	-0.84	0.64	0.28	0.08	0.64	0.76	0.42	0.94	0.85	0.7	0.25	0.9	0.6	0.95	-0.89	0.6	-0.89		0.41
Short Long Term Debt Total	0.13	0.13	0.14	0.13	0.43	0.21	-0.01	-0.66	0.1	-0.11	0.72	0.1	0.51	0.25	0.42	0.1	0.13	-0.13	0.47	0.18	0.46	-0.51	-0.1	-0.52	0.41

Click cells to compare fundamentals

Bio Gene Account Relationship Matchups

Bio Gene fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	6.6M	5.0M	7.3M	3.8M	3.2M	5.0M
Other Current Liab	266.4K	504.6K	790.2K	455.2K	298.7K	384.0K
Total Current Liabilities	412.0K	592.7K	1.0M	573.9K	345.9K	466.3K
Total Stockholder Equity	6.0M	4.2M	6.3M	3.2M	2.8M	4.5M
Net Tangible Assets	4.6M	5.7M	3.9M	6.0M	6.9M	3.6M
Property Plant And Equipment Net	37.0K	22.7K	23.0K	14.6K	19.0K	26.0K
Net Debt	(5.5M)	(3.9M)	(6.3M)	(3.0M)	(2.2M)	(2.3M)
Retained Earnings	(9.5M)	(11.7M)	(14.5M)	(17.4M)	(19.6M)	(18.7M)
Cash	5.5M	3.9M	6.3M	3.0M	2.2M	4.1M
Non Current Assets Total	387.9K	336.7K	300.1K	254.8K	222.2K	271.5K
Non Currrent Assets Other	(387.9K)	(336.7K)	(300.1K)	(254.8K)	203.2K	213.3K
Cash And Short Term Investments	5.5M	3.9M	6.3M	3.0M	2.2M	4.1M
Common Stock Shares Outstanding	119.4M	137.2M	153.3M	167.8M	185.8M	141.8M
Liabilities And Stockholders Equity	6.6M	5.0M	7.3M	3.8M	3.2M	5.0M
Other Stockholder Equity	950.0K	863.3K	1.2M	818.5K	941.2K	715.1K
Total Liab	567.3K	754.6K	1.0M	613.9K	368.4K	601.7K
Total Current Assets	6.2M	4.7M	7.0M	3.6M	2.9M	4.6M
Accumulated Other Comprehensive Income	950.0K	863.3K	1.2M	1.1M	907.0K	743.2K
Intangible Assets	351.0K	314.0K	277.1K	240.1K	203.2K	252.5K
Common Stock	11.8M	14.5M	15.1M	19.5M	21.5M	13.0M
Property Plant Equipment	37.0K	22.7K	23.0K	14.6K	16.8K	26.6K
Net Receivables	483.0K	523.8K	438.2K	445.6K	524.0K	401.8K
Accounts Payable	134.0K	88.1K	219.0K	118.7K	47.2K	44.9K
Non Current Liabilities Total	155.3K	161.9K	25.5K	40.0K	22.5K	21.4K
Inventory	102.6K	132.9K	148.8K	70.2K	80.7K	84.8K
Short Term Investments	4.3M	5.3M	74.2K	1.5M	1.4M	2.6M
Net Invested Capital	6.0M	4.2M	6.3M	3.2M	2.8M	4.4M
Property Plant And Equipment Gross	32.7K	37.0K	52.2K	50.5K	56.2K	47.9K
Net Working Capital	5.8M	4.1M	6.0M	3.0M	2.6M	4.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Bio Stock Analysis

When running Bio Gene's price analysis, check to measure Bio Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Gene is operating at the current time. Most of Bio Gene's value examination focuses on studying past and present price action to predict the probability of Bio Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Gene's price. Additionally, you may evaluate how the addition of Bio Gene to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC